Testing a new drug for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IPF, and a chest CT scan shows a pattern typical of this condition.
- Your breathing test results must be at least 45% of what is normal for your age and size.
- Your lung's ability to take in oxygen must be between 25% and 90% of normal.
- You are either not taking IPF medications, or you have been on a stable dose of nintedanib, pirfenidone, or nerandomilast for at least 12 weeks.
- You have not had a sudden worsening of your IPF in the last 3 months.
- You do not have other lung diseases, significant heart problems, or low blood pressure, and you have not had major surgery in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests the long-term safety and effectiveness of an oral medication (HSK44459) in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. If you were in the earlier study profile, this study lets you keep taking the medication to see if it continues to help over time.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.